BillionToOne(NASDAQ) BLLN

BillionToOne, Inc. makes blood tests that find tiny genetic markers. These tests help doctors monitor pregnancies and cancer treatment progress. The technology measures individual DNA molecules to improve medical accuracy.

What Does BillionToOne Do?

• Prenatal Screening: Non-invasive tests used to assess genetic risks in fetuses from maternal blood; accounts for 88% of revenue for the six months ended June 30, 2026.
• Oncology Diagnostics: Liquid biopsies that identify tumor mutations and track patient response to therapy; accounts for 11% of revenue for the six-month period ended June 30, 2026.
• Clinical Trial Support: Specialized services for pharmaceutical partners like Johnson & Johnson; represented 1% of revenue for the six months ended June 30, 2026.
• Confirmation Assays: Tools that isolate intact fetal cells to verify high-risk screening results without using invasive procedures.
• Decision Support Tools: Add-on applications for oncology tests that address chemotherapy safety and identify tumor tissue of origin.

Expanding Laboratory Capacity

• Launched the UNITY prenatal test in 2019 to provide genetic risk assessments.
• Introduced the Northstar Select and Northstar Response liquid biopsy tests in 2023 to enter the oncology market.
• Added a 90,000 square foot laboratory facility in Union City, California, in 2023.
• Announced the launch of the Northstar Origin feature and a 130-gene prenatal panel in Aug. 2026.
• Expanded Union City operations in June 2026 by leasing a third laboratory facility.

Precision at the Molecular Level

The company uses single-molecule counting to find disease signals in cell-free DNA (cfDNA), which are tiny DNA fragments found in the blood. It also integrates artificial intelligence into its billing systems to process insurance claims more efficiently as testing volumes increase.

Strong Momentum in the Results

• Revenue reached $109.4 million for the three months ended June 30, 2026, up 64.4% year over year.
• Net income was $8.1 million for the quarter ended June 30, 2026, compared to a net loss of $246,000 in the prior year.
• Billable test volume grew 35% to 196,000 for the three-month period ended June 30, 2026.
• Market capitalization stood at $6.9 billion according to recent data.
• Cash and cash equivalents totaled $548.6 million as of June 30, 2026.

Company Evolution

BillionToOne has evolved from a research organization into a commercial diagnostic provider serving both prenatal and oncology markets. Its focus on single-molecule precision and automated operations supports its ability to scale while improving profitability.